In the Phase III BREAKWATER Trial, a Braftovi-based regimen demonstrated improved survival outcomes in patients with metastatic colorectal cancer (CRC) harboring the BRAF V600E mutation. Encorafenib, a potent and selective BRAF inhibitor, exerts antiproliferative and apoptotic effects in tumor cells with BRAF V600E mutations. Unlike other BRAF inhibitors, Encorafenib has prolonged pharmacodynamic activity. In colorectal […]